Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul;34(3):154-8.
doi: 10.4103/0971-5851.123711.

Chronic myeloid leukemia data from India

Shweta Bansal  1 , Kumar Prabhash  2 , Purvish Parikh  3
Affiliations

Chronic myeloid leukemia data from India

Shweta Bansal et al. Indian J Med Paediatr Oncol. 2013 Jul.

Abstract

In an effort to collaborate the data of chronic myeloid leukemia (CML) patient from all over India,meeting was conceived by ICON (Indian Cooperative Oncology Network) in 2010. This article presents the summarized picture of the data presented in the meeting. In the meeting 8115 patients data was presented and 18 centres submitted their manuscripts comprising of 6677 patients. This data represents large series of patients from all over the country treated on day to day clinical practice and presents the actual outcomes of CML patients in India. The compilation of data confirms the younger age at presentation, increased incidence of resistance and poor outcomes in patients with late chronic phase. It also addresses the issues like Glivec versus Generic drug outcomes, safety of Imatinib during pregnancy and mutational analysis among resistant patients. It concludes that survival and quality of life of CML patients in India has improved over the years especially when treated in early chronic phase. The generic drug is a good option where original is unable to reach the patient due to various reasons. Hopefully, this effort will provide a platform to conduct systematic studies in learning the best treatment options among CML patients in Indian settings.

Keywords: Chronic myeloid leukemia; India; Indian cooperative oncology network; mylestone.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Map of India showing location of 22 Oncology centers represented at myelstone chronic myeloid leukemia meeting July 2010
Figure 2
Figure 2
Number of patients from various oncology centers represented at myelstone – Chronic myeloid leukemia meeting July 2010
Figure 3
Figure 3
Chronic myeloid leukemia phase at the time of diagnosis
Figure 4
Figure 4
Sokal risk category at the time of chronic myeloid leukemia diagnosis
See this image and copyright information in PMC

Comment on

  • Indian J Med Paediatr Oncol. 34(3):151.

References

    1. Lee SJ. Chronic myelogenous leukaemia. Br J Haematol. 2000;111:993–1009. - PubMed
    1. Deininger MW, O’Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21:1637–47. - PubMed
    1. Leitner AA, Hehlmann R. Modern therapy of chronic myeloid leukemia: an example for paradigma shift in Hemato-oncology. Internist (Berl) 2011;52:209–17. - PubMed
    1. O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: Sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM) Blood. 2008;112:76.
    1. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. [Last accessed on 2013 nov 6];J Clin Oncol. 2009 27:6041–51. Available from: http://www.oncologyindia.org/myelstone . - PMC - PubMed